Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Slightly Bullish +25

CureVac files Covid-19 vaccine lawsuit against Moderna - CDR News

🔬 CureVac, a German biotech company, has filed a lawsuit against Moderna in the US District Court for the District of Delaware.

⚖️ The legal action was filed on April 24, 2026, alleging infringement of patented innovations related to Covid-19 vaccine therapeutics.

💰 CureVac is seeking recovery of royalties from Moderna's profits generated by its Covid-19 vaccines.

👥 The German company is requesting a jury trial as part of its legal demand against the pharmaceutical giant.

⚠️ This lawsuit centers on intellectual property disputes regarding mRNA technology specifically used in pandemic-era vaccines.

📅 The article was published on April 27, 2026, by Natasha Doris for CDR News.

🏢 Moderna is described as a major pharmaceutical entity being targeted by the German biotech firm's claims.

Bullish Signals
  • CureVac filed a lawsuit against Moderna in the US District Court for the District of Delaware, asserting its patented mRNA therapeutics innovations. This legal action could secure royalty recovery from Moderna's profits related to Covid-19 vaccines.
  • The filing was submitted on 24 April 2026, with CureVac requesting a jury trial and damages based on patent infringement claims.
  • CureVac is leveraging its intellectual property portfolio to challenge market competition in the mRNA sector.
Risk Factors
  • German biotech CureVac has filed a lawsuit against pharmaceutical giant Moderna in the US District Court for the District of Delaware, alleging infringement on patented innovations for mRNA therapeutics.
  • The lawsuit, filed on April 24, 2026, demands a jury trial and recovery of royalties from Moderna's profits garnered from its Covid-19 vaccines, potentially exposing Moderna to significant financial liabilities.
  • Moderna faces direct intellectual property accusations regarding its Covid-19 vaccine development, which could disrupt its commercial operations and create legal precedents affecting other mRNA therapeutics.
Full Analysis
CureVac, a German biotechnology company, has filed a lawsuit against American pharmaceutical giant Moderna in the US District Court for the District of Delaware regarding alleged patent infringements on its Covid-19 vaccine. The suit was filed on April 24, 2026, and CureVac claims that Moderna has violated its patented innovations specifically related to mRNA therapeutics used in Covid-19 vaccines. In the complaint, CureVac is seeking a jury trial and requests damages calculated as royalties based on the profits Moderna has reportedly garnered from selling its Covid-19 vaccines. The core of the dispute centers on intellectual property rights within the rapidly evolving field of mRNA technology. By filing this lawsuit in Delaware, CureVac highlights the significance of the US legal system for international biotech litigation regarding global vaccine distribution and revenue. The request to recover royalties suggests that CureVac views Moderna's commercial success with its vaccines as a direct result of using proprietary technology developed under CureVac's patents. This legal action could have significant implications for the competitive landscape of mRNA therapeutics, potentially setting precedents for future patent disputes in the sector.